Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

FDA Approves The First 3D Printed Drug Product

BLUE ASH, Ohio, Aug. 3, 2015 /PRNewswire/ — Aprecia Pharmaceuticals Company today announced that the U.S. Food and Drug Administration (FDA) has approved SPRITAM® levetiracetam for oral use as a prescription adjunctive therapy in the treatment of partial onset seizures, myoclonic seizures and primary generalized tonic-clonic seizures in adults and children with epilepsy.[1] SPRITAM utilizes Aprecia’s […]

Read More »

New Publications Show Promise of Improved Artificial Lung Devices

PITTSBURGH–(BUSINESS WIRE)–ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, today announced the publication of new data by University of Pittsburgh researchers on two groundbreaking technologies it has previously licensed from the University. The new technologies, which help enhance the performance of artificial […]

Read More »

Deloitte Report: Health Insurance Exchanges May Spark Consumerism

NEW YORK, Aug. 3, 2015 /PRNewswire/ — People who obtain health insurance through the public exchanges (HIX) show signs of acting more like savvy shoppers versus passive patients when engaging the health system, according to the Deloitte report, “Public Health Exchanges – Opening the Door for a New Generation of Engaged Health Care Consumers.” Produced by […]

Read More »

Bristol-Myers Squibb Establishes Collaborative Immuno-Oncology Rare Population Malignancy (I-O RPM) Program in the U.S.

NEW YORK & CHICAGO–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) today announced the establishment of the Immuno-Oncology Rare Population Malignancy (I-O RPM) program in the U.S. The I-O RPM program is a multi-institutional initiative with academic-based cancer centers focused on the clinical investigation of Immuno-Oncology therapeutics as potential treatment options for patients with high risk, poor prognostic […]

Read More »

Pfizer and Synthon Enter Into U.S. Commercialization Agreement for Potential Generic Treatment of Multiple Sclerosis

Pfizer Inc. and Synthon, an international pharmaceutical company specializing in the development of complex generic medicines, today announced they have entered into an agreement whereby Pfizer has acquired the exclusive commercialization rights in the United States to glatiramer acetate, a potential generic version of the originator medicine Copaxone® for the treatment of relapsing remitting multiple […]

Read More »

Brain training app could help people with schizophrenia

A “brain training” iPad game developed in Britain may improve the memory of patients with schizophrenia, helping them in their daily lives at home and at work, researchers said on Monday. Scientists at Cambridge University said tests on a small number of patients who played the game over four weeks found they had improvements in […]

Read More »

Samsung Electronics to create fund for cancer-stricken workers, safety

Tech giant Samsung Electronics Co Ltd said on Monday it will create a 100 billion won ($85.8 million) fund to compensate cancer-stricken workers and their families, and for efforts to prevention such diseases at its chip and display factories. Samsung said in a statement the fund will make payments to workers or families of those […]

Read More »

Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the pivotal TELESTAR Phase 3 clinical trial met its primary endpoint, showing the benefit of oral telotristat etiprate in treating cancer patients with carcinoid syndrome that is not adequately controlled by the current standard of care. Telotristat etiprate was discovered using Lexicon’s gene science, based on Nobel […]

Read More »

AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases

CARLSBAD, Calif., Aug. 3, 2015 /PRNewswire/ — Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) and AstraZeneca today announced a strategic collaboration to discover and develop antisense therapies for cardiovascular, metabolic and renal diseases. The new collaboration builds on a broad existing relationship between the two companies and supports AstraZeneca’s strategic approach in these therapeutic areas using novel RNA-targeted […]

Read More »

Ipsen’s Partner, Lexicon Pharmaceuticals, Announces Positive Results from TELESTAR Phase 3 Study Showing That Telotristat Etiprate is Effective in the Treatment of Carcinoid Syndrome Caused by Neuroendocrine Tumors Not Adequately Controlled by Somatostatin …

PARIS–(BUSINESS WIRE)–Regulatory News: Ipsen’s Partner, Lexicon Pharmaceuticals, Announces Positive Results from TELESTAR Phase 3 Study Showing That Telotristat Etiprate is Effective in the Treatment of Carcinoid Syndrome Caused by Neuroendocrine Tumors Not Adequately Controlled by Somatostatin Analogs Telotristat etiprate met the primary endpoint, i.e. reduction from baseline compared to placebo in the average number of […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom